Business Wire

DE-CSC

Share
CSC Partners with NetDiligence to Help Mitigate Cyber Risks and Support the Cyber Insurance Ecosystem

CSC, an enterprise-class domain registrar and world leader in mitigating domain security, domain name system (DNS), and digital brand threats, today announces its partnership with NetDiligence®, a leader in cyber risk readiness and response solutions for the cyber insurance industry. With this agreement, CSC is now an available vendor to cyber insurance carriers, brokers, and clients on NetDiligence’s eRiskHub® under the newly developed “pre-breach” category: brand protection and domain security.

CSC’s innovative technology allows cyber insurance carriers, brokers, and clients alike to proactively protect their businesses against cyber threats and online brand abuse. “As a preferred vendor to cyber insurance leaders, it’s critical to address cybersecurity gaps and help companies keep losses at a minimum,” says Mark Greisiger, president of NetDiligence. “We’re excited to introduce CSC’s domain security and digital brand protection solutions on our eRiskHub platform because it will provide our users with new ways to address risk and cyber threats such as phishing, business email compromise, and ransomware.”

An overwhelming majority of companies overlook their domain security posture as part of a larger risk management plan for their business. For corporations operating multiple brands—with hundreds or even thousands of domains within their portfolios—it’s crucial to have rapid detection and deactivation of confusingly similar domains imitating brands, as well as any compromised, hijacked domains, or subdomains that may exist.

“As the world’s leading enterprise-class domain registrar, CSC can detect domain threats, online brand and DNS abuse, and fraud quickly to protect companies from fraudulent or compromised domains that lead to devastating cyber attacks,” says Mark Calandra, president of CSC’s Digital Brand Services division. “Our inclusion in eRiskHub creates visibility for our services directly within the workflow of users looking to optimize their cyber security posture.”

Within the eRiskHub, CSC’s solutions will be categorized into three services: digital brand protection, domain registrar services, and fraud protection. To access pre-breach brand protection and domain security solutions, visit the eRiskHub. Additionally, on February 12 at 11:30 a.m., CSC’s Digital Brand Services Chief Technology Officer Ihab Shraim and AXA XL’s Gwenn Cujdik, North America Cyber Incident Response Team, will be speaking on the Pathways to Resilience panel, Domain Security: Addressing Cybersecurity at the Source of the Problem. To contact CSC directly, visit cscdbs.com.

About CSC

CSC is the trusted security and threat intelligence provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® with focus areas in domain security and management, along with digital brand and fraud protection. As global companies make significant investments in their security posture, our DomainSecSM platform can help them understand cybersecurity oversights that exist and help them secure their online digital assets and brands. By leveraging CSC’s proprietary technology, companies can solidify their security posture to protect against cyber threat vectors targeting their online assets and brand reputation, helping them avoid devastating revenue loss. CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—with a multidimensional view of various threats outside the firewall targeting specific domains. Fraud protection services that combat phishing in the early stages of attack round out our solutions. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia- Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.

About NetDiligence

NetDiligence® specializes in Cyber Risk Readiness & Response services. With over 20 years of experience in cyber, NetDiligence is an award-winning provider of innovative cyber risk management software and services to the insurance industry, including QuietAudit® Cyber Risk Assessments, the eRiskHub® cyber risk management portal, their authorized Breach Coach® program, and Breach Plan Connect®, a securely hosted solution designed to help senior managers plan and execute their organization’s response to a cyber incident, which also includes a free mobile app for convenient access and alternative means of communication if company systems are compromised. NetDiligence publishes an annual Cyber Claims Study and traditionally hosts their Cyber Risk Summit conferences in Philadelphia, California, Toronto, Florida, London, and Bermuda. For more information, visit NetDiligence.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240212855330/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press release

Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent skin lesions, and affects approximately up to 40 million people in the European Union (EU)1-4 Prurigo nodularis is a serious skin disease characterized by chronic itch, skin nodules covering large body areas, and poor sleep quality, which is estimated to affect up to 111 people per 100,000 in the EU5-10 Nemolizumab is a first-in-class monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31.2 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis11-13 This positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommending the granting of marketing authorization of nemolizumab in the European Union (EU) for the treatment of both atopic dermatitis and prurigo n

FPT and DENSO Sign MOU to Accelerate Software-Defined Vehicle Innovation13.12.2024 06:58:00 CET | Press release

Global IT corporation FPT and global automotive components manufacturer DENSO signed a Memorandum of Understanding (MOU) to collaborate on advancing software-defined vehicles (SDV). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212915049/en/ The signing ceremony took place at DENSO Corporation Aichi Headquarters with the participation of Dr Truong Gia Binh, Chairman of FPT Corporation, Mr Shinnosuke Hayashi, President & CEO of DENSO Corporation, and senior leaders of both companies. (Photo: Business Wire) Under this MOU, the two companies will develop software for next-generation SDVs, with a particular emphasis on mass-production projects for Advanced Driver Assistance Systems (ADAS). Both companies aim to build a high-speed, high-quality global development framework, with plans for expansion by the end of 2027. The partnership is backed by FPT’s two decades of experience in automotive, a global team of 5,000 automotive

Kao Corporation: Regarding Shareholder Statement13.12.2024 05:48:00 CET | Press release

Oasis Management Company Ltd. (hereinafter referred to as “Oasis Management”), an investment management firm and a shareholder of our company, released a statement regarding Director candidates to be proposed at our 119th Ordinary General Meeting of Shareholders. Kao's Board of Directors and management team strive to increase shareholder value from a long-term perspective based on our business strategy. For the purpose of enhancing our corporate value, we are committed to engaging directly and constructively with all our stakeholders and welcome new perspectives to address challenges. Kao is constantly evolving its selection process to ensure an optimal composition of the Board of Directors. This year, the Committee for Examination of Nominees for Directors and Audit & Supervisory Board Members spent more than six months discussing the matter before reaching a final decision, and the decision was made before Oasis Management proposed any director candidates. The timing of the announcem

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor13.12.2024 01:30:00 CET | Press release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15 percent of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer. “With one of the most dynamic solid tumor portfolios in the industry, we are continually assessing opportunities that align with our strategic focus and address significant unmet needs for patients. This MAT2A inhibitor is a valuable addition to our solid tumor pipeline, and we’re eager to explore its potential, particularly in combination with our internally de

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas12.12.2024 23:30:00 CET | Press release

Six Late-Stage Programs with Peak Revenue Potential of $10B - $20B1 Poised to Deliver Sustainable GrowthExpected Phase 3 Data Readouts in 2025 for Oveporexton (TAK-861), Zasocitinib (TAK-279) and Rusfertide (TAK-121)Regulatory Filings for Oveporexton (Narcolepsy Type 1), Zasocitinib (Psoriasis) and Rusfertide (Polycythemia Vera) on Track for Fiscal Years 2025 - 2026Five Additional Filings Anticipated in Fiscal Years 2027 - 2029 Including First Indication Submissions for Mezagitamab (TAK-079), Fazirsiran (TAK-999) and Elritercept (TAK-226) Takeda (TSE:4502/NYSE:TAK) willhost an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the company’s late-stage pipeline, the transformative value they could deliver to patients, and the market opportunities they represent. “We are focused on advancing our innovative pipeline and accelerating late-stage programs to deliver sustainable revenue growth to 2030 and beyond, building upon the strong momentum

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye